Glycation during storage and administration of monoclonal antibody formulations

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 70, Issue 1, 2008, Pages 42-50

  Fischer, Stefan ^a   Hoernschemeyer, Joerg ^a   Mahler, Hanns Christian ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Administration; Antibody; Compatibility; Formulation; Glucose; Glycation; Sucrose

Indexed keywords

BORONIC ACID DERIVATIVE; GLUCOSE; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; MONOSACCHARIDE;

AFFINITY CHROMATOGRAPHY; ARTICLE; BORONATE AFFINITY CHROMATOGRAPHY; CHO CELL; CONTROLLED STUDY; COVALENT BOND; DILUTION; DRUG FORMULATION; DRUG QUALITY; DRUG STORAGE; ELECTROSPRAY MASS SPECTROMETRY; FERMENTATION; GLYCATION; HUMAN; HUMAN CELL; HYDROLYSIS; INCUBATION TIME; INFUSION SYSTEM; LIQUID CHROMATOGRAPHY; NONHUMAN; PROTEIN MODIFICATION; QUANTITATIVE ASSAY; REACTION ANALYSIS; RISK; SHELF LIFE; STORAGE;

ANTIBODIES, MONOCLONAL; BUFFERS; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, AFFINITY; CHROMATOGRAPHY, LIQUID; DRUG STABILITY; DRUG STORAGE; EQUIPMENT DESIGN; EXCIPIENTS; FERMENTATION; GLUCOSE; GLYCOSYLATION; HUMANS; HYDROGEN-ION CONCENTRATION; HYDROLYSIS; INFUSIONS, PARENTERAL; OXIDATION-REDUCTION; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SUCROSE; TECHNOLOGY, PHARMACEUTICAL; TIME FACTORS;

EID: 50349097199     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2008.04.021     Document Type: Article

References (45)

1. Pavlou A.K., and Belsey M.J. The therapeutic antibodies market to 2008. Eur. J. Pharm. Biopharm. 59 (2005) 389-396
2. Murphy R.M., and Kendrick B.S. Protein misfolding and aggregation. Biotechnol. Prog. 23 (2007) 548-552
3. Wang W., Singh S., Zeng D.L., King K., and Nema S. Antibody structure, instability, and formulation. J. Pharm. Sci. 96 (2007) 1-26
4. Cao E., Chen Y., Cui Z., and Foster P.R. Effect of freezing and thawing rates on denaturation of proteins in aqueous solutions. Biotechnol. Bioeng. 82 (2003) 684-690
5. Tanford C. Protein denaturation. Adv. Protein Chem. 23 (1968) 121-282
6. Wang W. Protein aggregation and its inhibition in biopharmaceutics. Int. J. Pharm. 289 (2005) 1-30
7. Baynes B.M., Wang D.I., and Trout B.L. Role of arginine in the stabilization of proteins against aggregation. Biochemistry 44 (2005) 4919-4925
8. Cleland J.L., Powell M.F., and Shire S.J. The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Crit. Rev. Ther. Drug Carrier Syst. 10 (1993) 307-377
9. Marcon G., Plakoutsi G., and Chiti F. Protein aggregation starting from the native globular state. Methods Enzymol. 413 (2006) 75-91
10. Souillac P.O., Uversky V.N., Millett I.S., Khurana R., Doniach S., and Fink A.L. Effect of association state and conformational stability on the kinetics of immunoglobulin light chain amyloid fibril formation at physiological pH. J. Biol. Chem. 277 (2002) 12657-12665
11. Johnston T.P. Adsorption of recombinant human granulocyte colony stimulating factor (rhG-CSF) to polyvinyl chloride, polypropylene, and glass: effect of solvent additives. PDA J. Pharm. Sci. Technol. 50 (1996) 238-245
12. Miller R., Fainerman V.B., Makievski A.V., Kragel J., and Wustneck R. Adsorption characteristics of mixed monolayers of a globular protein and a non-ionic surfactant. Colloids Surf. A 161 (2000) 151-157
13. Mollmann S.H., Bukrinsky J.T., Frokjaer S., and Elofsson U. Adsorption of human insulin and AspB28 insulin on a PTFE-like surface. J. Colloid Interface Sci. 286 (2005) 28-35
14. Carpenter J.F., Kendrick B.S., Chang B.S., Manning M.C., and Randolph T.W. Inhibition of stress-induced aggregation of protein therapeutics. Methods Enzymol. 309 (1999) 236-255
15. Zhao F., Ghezzo-Schoneich E., Aced G.I., Hong J., Milby T., and Schoneich C. Metal-catalyzed oxidation of histidine in human growth hormone. Mechanism, isotope effects, and inhibition by a mild denaturing alcohol. J. Biol. Chem. 272 (1997) 9019-9029
16. Uversky V.N., Yamin G., Souillac P.O., Goers J., Glaser C.B., and Fink A.L. Methionine oxidation inhibits fibrillation of human alpha-synuclein in vitro. FEBS Lett. 517 (2002) 239-244
17. Soenderkaer S., Carpenter J.F., van de Weert M., Hansen L.L., Flink J., and Frokjaer S. Effects of sucrose on rFVIIa aggregation and methionine oxidation. Eur. J. Pharm. Sci. 21 (2004) 597-606
18. Reubsaet J.L., Beijnen J.H., Bult A., van Maanen R.J., Marchal J.A., and Underberg W.J. Analytical techniques used to study the degradation of proteins and peptides: chemical instability. J. Pharm. Biomed. Anal. 17 (1998) 955-978
19. Breen E.D., Curley J.G., Overcashier D.E., Hsu C.C., and Shire S.J. Effect of moisture on the stability of a lyophilized humanized monoclonal antibody formulation. Pharm. Res. 18 (2001) 1345-1353
20. Chelius D., Rehder D.S., and Bondarenko P.V. Identification and characterization of deamidation sites in the conserved regions of human immunoglobulin gamma antibodies. Anal. Chem. 77 (2005) 6004-6011
21. DePaolis A.M., Advani J.V., and Sharma B.G. Characterization of erythropoietin dimerization. J. Pharm. Sci. 84 (1995) 1280-1284
22. Watkins N.G., Thorpe S.R., and Baynes J.W. Glycation of amino groups in protein. Studies on the specificity of modification of RNase by glucose. J. Biol. Chem. 260 (1985) 10629-10636
23. Horvat S., and Jakas A. Peptide and amino acid glycation: new insights into the Maillard reaction. J. Pept. Sci. 10 (2004) 119-137
24. Ahmed N., Babaei-Jadidi R., Howell S.K., Beisswenger P.J., and Thornalley P.J. Degradation products of proteins damaged by glycation, oxidation and nitration in clinical type 1 diabetes. Diabetologia 48 (2005) 1590-1603
25. Bierhaus A., Hofmann M.A., Ziegler R., and Nawroth P.P. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovas. Res. 37 (1998) 586-600
26. Brownlee .M. Advanced protein glycosylation in diabetes and aging. Annu. Rev. Med. 46 (1995) 223-234
27. Singh .R., Barden A., Mori T., and Beilin L. Advanced glycation end-products: a review. Diabetologia 44 (2001) 129-146
28. Lapolla A., Fedele D., and Traldi P. The role of mass spectrometry in the study of non-enzymatic protein glycation in diabetes. Mass Spectrom. Rev. 19 (2000) 279-304
29. Ulrich P., and Cerami A. Protein glycation, diabetes, and aging. Recent Prog. Horm. Res. 56 (2001) 1-21
30. Wautier J.L., and Guillausseau P.J. Diabetes, advanced glycation endproducts and vascular disease. Vasc. Med. 3 (1998) 131-137
31. Basta G., Lazzerini G., Massaro M., Simoncini T., Tanganelli P., Fu C., Kislinger T., Stern D.M., Schmidt A.M., and De Caterina R. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 105 (2002) 816-822
32. Bierhaus A., Illmer T., Kasper M., Luther T., Quehenberger P., Tritschler H., Wahl P., Ziegler R., Muller M., and Nawroth P.P. Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE. Circulation 96 (1997) 2262-2271
33. Duraisamy Y., Slevin M., Smith N., Bailey J., Zweit J., Smith C., Ahmed N., and Gaffney J. Effect of glycation on basic fibroblast growth factor induced angiogenesis and activation of associated signal transduction pathways in vascular endothelial cells: possible relevance to wound healing in diabetes. Angiogenesis 4 (2001) 277-288
34. Virella G., Thorpe S.R., Alderson N.L., Stephan E.M., Atchley D., Wagner F., and Lopes-Virella M.F. Autoimmune response to advanced glycosylation end-products of human LDL. J. Lipid Res. 44 (2003) 487-493
35. Bouma B., Kroon-Batenburg L.M., Wu Y.P., Brunjes B., Posthuma G., Kranenburg O., de Groot P.G., Voest E.E., and Gebbink M.F. Glycation induces formation of amyloid cross-beta structure in albumin. J. Biol. Chem. 278 (2003) 41810-41819
36. Obrenovich M.E., and Monnier V.M. Glycation stimulates amyloid formation. Sci. Aging Knowledge Environ. 2004 (2004) pe3
37. Harris .R.J. Heterogeneity of recombinant antibodies: linking structure to function. Dev. Biol. (Basel) 122 (2005) 117-127
38. Quan C.P., Wu S., Dasovich N., Hsu C., Patapoff T., and Canova-Davis E. Susceptibility of rhDNase I to glycation in the dry-powder state. Anal. Chem. 71 (1999) 4445-4454
39. Townsend M.W., and DeLuca P.P. Use of lyoprotectants in the freeze-drying of a model protein, ribonuclease A. J. Parenter. Sci. Technol. 42 (1988) 190-199
40. Gadgil H.S., Bondarenko P.V., Pipes G., Rehder D., McAuley A., Perico N., Dillon T., Ricci M., and Treuheit M. The LC/MS analysis of glycation of IgG molecules in sucrose containing formulations. J. Pharm. Sci. 96 (2007) 2607-2621
41. In: Rowe R.C., Sheskey P.J., and Owen S.C. (Eds). Pharmaceutical Excipients (2007), Pharmaceutical Press and American Pharmacists Association
42. Quan C., Alcala E., Petkovska I., Matthews D., Canova-Davis E., Taticek R., and Ma S. A study in glycation of a therapeutic recombinant humanized monoclonal antibody: where it is, how it got there, and how it affects charge-based behavior. Anal. Biochem. 373 (2008) 179-191
43. Zhang B., Yang Y., Yuk I., Pai R., McKay P., Eigenbrot C., Dennis M., Katta V., and Francissen K.C. Unveiling a glycation hot spot in a recombinant humanized monoclonal antibody. Anal. Chem. 80 (2008) 2379-2390
44. H. Liu, H. Flores, M. Maier, B. Zhang, M. Cromwell, Effect of protein glycation on the stability of a humanized monoclonal antibody, in: 232nd ACS National Meeting, San Francisco, CA, United States, 2006.
45. Gil H., Salcedo D., and Romero R. Effect of phosphate buffer on the kinetics of glycation of proteins. J. Phys. Org. Chem. 18 (2005) 183-186